Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Abnormal Serum Potassium Level

Clin J Am Soc Nephrol. 2021 Jul;16(7):1094-1096. doi: 10.2215/CJN.02130221. Epub 2021 Jul 12.

Y Joseph Hwang^{1

2}, Beini Lyu³, Alex R Chang⁴, Lesley A Inker⁵, Morgan E Grams^{1

2

6

7}, Jung-Im Shin^{2

6

7}

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland.
³ Department of Population Health Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.
⁴ Kidney Health Research Institute, Geisinger Health, Danville, Pennsylvania.
⁵ Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
⁶ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁷ Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland.

No abstract available

Keywords: SGLT2i; hyperkalemia; hypokalemia; potassium; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes mellitus.

Publication types